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RESUMO – O conhecimento do processo de evolução tumoral é essencial para compreender os alvos terapêuticos no controle 
da doença. A forma como o sistema imune influência o desenvolvimento e a progressão do cancro é uma questão desafiante na 
área da imunologia. Atualmente reconhece-se o papel paradoxal do sistema imunológico neste processo: por um lado protege 
contra o crescimento tumoral, destruindo células exprimindo antigénios tumorais “aberrantes”, por outro pode favorecer a sua 
progressão, selecionando células tumorais que escapam à vigilância imunológica e são capazes de sobreviver num hospedeiro 
imunocompetente. Esta observação deu origem ao conceito de “cancer immunoediting”, que explica a influência do sistema 
imune na progressão tumoral. Tendo em conta algumas observações associadas ao melanoma, como por exemplo, o desenvol-
vimento de vitiligo, a possibilidade de regressão e a correlação com a imunossupressão, este tem sido considerado um exemplo 
de tumor imunogénico, cujo mecanismo patofisiológico reconhecido até à data se enquadra no conceito de “immunoediting”. 
Reconhecida a importância de CTLA-4 (antigénio linfócitário T citotóxico) e PD-1 (proteína de morte celular programada) como 
“checkpoints” imunológicos na regulação da atividade das células T em resposta à progressão tumoral, estas moléculas têm 
sido considerados alvos terapêuticos importantes no tratamento do melanoma avançado. O presente artigo pretende rever su-
cintamente o processo de evolução tumoral e respetiva interação com o sistema imune, bem como o mecanismo de ação dos 
“checkpoints” inibitórios por forma a melhor compreender os novos alvos da imunoterapia no melanoma avançado, que serão 
revistos em trabalho futuro.
PALAVRAS-CHAVE – Imunoterapia; Melanoma/imunologia; Melanoma/tratamento; Receptor de Morte Celular Programada 
1;Vigilância Imunológica.
Immune Response in Melanoma: A Basis to 
Understand the Role of Immunotherapy with Immune 
Checkpoint Inhibitors  
ABSTRACT – The knowledge of the pathophysiology of tumour progression is crucial to understand the therapeutic targets in 
order to control the disease. The mechanisms used by the immune system to affect cancer development and progression has been 
a challenging question in immunology. It is now postulated that immunology plays a dual role in this process: it protects against 
tumour growth, destroying “aberrant” tumour cells, but may also promote tumour progression by selecting tumour cells that are 
able to escape the immune response and survive in an immunocompetent host. These findings gave rise to the concept of “cancer 
immunoediting”, which explains the influence of the immune system on tumour progression. Several observations like immuno-
suppression as a risk factor for melanoma, the possibility of partial or complete regression of primary tumour and development 
of vitiligo, have suggested that melanoma is an immunogenic tumour but a successful tumour evolution can occur in the light of 
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INTRODUCTION
The way the immune system influences tumour develo-
pment has long been a subject of discussion. In the 50's, 
Burnet highlighted the importance of adaptive immunity in 
preventing cancer development in immunocompetent hosts, 
originating the concept of “cancer immunosurveillance”.1 
Notwithstanding, further experimental studies showing that 
cancer susceptibility in immunocompetent mice was simi-
lar to immunodeficient mice2,3 pulled down the “cancer im-
munosurveillance” hypothesis. The idea of immunity and 
tumour progression had started with the demonstration of 
tumour antigens.4 Later, other authors argued that tumours 
result from transformation of normal cells with unregulated 
growth control, thereby tumour immunity would resemble 
immunity to normal tissues with the immune system recog-
nizing tumour antigens as “self”.5 Moreover, persistent ac-
tivation of the innate immune system in pro-inflammatory 
states may promote cancer development in this tumour mi-
croenvironment.6,7 Nevertheless, the concept of cancer im-
munosurveillance was rekindled by the discovery of the effect 
of interferon-gamma (IFN-γ) in promoting immunologically 
induced rejection of transplanted tumour cells, showing the 
crucial role of IFN-γ in promoting tumour cell recognition 
and elimination.8 Additional studies documented the impor-
tance of immune system in cancer suppression.9
Based on the previous findings, it is currently warrantable 
that immune system has a dual role in cancer development. 
As it protects against foreign pathogens and controls inflam-
mation it eliminates certain tumour cells and, consequently, 
the link between immunosuppression and increased cancer 
risk is widely established.10 On the other hand and despite a 
normal host immune system, tumours develop evasion me-
chanisms in which the immune system shapes the immuno-
genic phenotype of the tumor preventing their antigens to be 
immune targets,11 therefore avoiding immunological elimi-
nation of the tumour cells.12 Cancer immunoevasion, throu-
gh the modification of tumor cells or its microenvironment by 
the immune systems is considered within the process of im-
munoediting and has been regarded as an emergent “hall-
mark of cancer”.13 Thereby the term “cancer immunoediting” 
has been used to describe the dual role of immune system 
on cancer progression: host protection (“cancer immunosur-
veillance”) versus tumor promotion (“immunoevasion”).11,12
Due to new insights on the immune escape mechanisms, 
immunotherapy has recently emerged as an effective treat-
ment approach.14 Particularly in melanoma that very likely 
progresses through the stages of cancer immunoediting,15 
the recognition of CTLA-4 and PD1/PD-L1 as targets to im-
mune checkpoint inhibitors revolutionized the treatment of 
this aggressive tumour.16-18 Herein we briefly review the pro-
cess of cancer immunoediting and the mechanisms of action 
of immune checkpoints inhibitors to contextualize immuno-
therapy in advanced melanoma. 
1. CANCER IMMUNOEDITING
Cancer immunoediting comprises 3 different phases: the 
elimination phase, the equilibrium phase and the immunolo-
gical escape phase19,20 (Fig. 1).
Elimination: The elimination phase underlies the concept 
of “cancer immunosurveillance”, in which both innate and 
adaptive immune response work together to eliminate detec-
ted foreign tumour cells. Main pathways crucial to recognize 
and eliminate the most immunologically vulnerable antigenic 
tumour cells include recognition molecules such as NKG2D 
important for NK cells, host effector molecules like interferon 
type I (IFN-α/β), interferon type II (INF-γ), perforin and Fas/
FasL, and effector cells like CD4+ and CD8+ T cells and B 
cells.9,19 In addition, NK cells and macrophages from inna-
te immune system improve surveillance of senescent tumour 
cells.9 Of outmost importance in this phase is the controlled 
release of pro-inflammatory and immunomodulatory media-
tors, which paradoxically may establish a microenvironment 
that facilitates tumour growth.21 Thus, a coordinated and ba-
lanced work of innate and adaptive immunity is needed to 
protect the host against a developing tumour and reach the 
primary endpoint of the elimination phase, a complete des-
truction of tumour cells.
Equilibrium: The equilibrium phase is poorly understood 
since it is very difficult to replicate in animal models.19 Ne-
vertheless, it is postulated that the adaptive immune system 
prevents tumour cell outgrowth and at same time sculpts the 
immunogenicity of the tumour cells.22 Perhaps the equili-
brium is the longest phase, were the immune system keeps 
residual tumour cells in a functional state of dormancy.20 
Using a mouse model, Koebel et al22 demonstrated that tu-
mour cells in equilibrium are highly immunogenic (unedited 
tumour cells), whereas those spontaneously exiting equili-
brium and that become growing tumours have attenuated 
immunogenicity (edited tumour cells). They also showed that 
the equilibrium phase is maintained solely by the adaptive 
immunity, while the eliminating phase requires the concerted 
action of adaptive and innate immunity. 
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Escape: In the escape phase tumour cells that have ac-
quired the ability to evade immune recognition progressively 
grow as visible tumours. Several mechanisms both from tu-
mour cells and the microenvironment have been proposed to 
explain immunological escape.9,11,14,23 
Immune recognition of tumour cells can be reduced by 
loss of tumour antigens perhaps in association with genetic 
instability,23 survival and emergence of tumour cells lacking 
“strong” antigens and by the loss of major histocompatibi-
lity complex (MHC) class I expression, preventing T cell re-
cognition of tumour antigens. Resistance to immune cytotoxic 
effects can increase due to the activation of pro-oncogenic 
transcription factors (e.g: MITF – melanogenesis associated 
transcription factor, STAT3 – signal transducer and activator of 
transcription 3, RUNX – runt related transcription factor, NF-kB 
– factor nuclear kB) or to the expression of anti-apoptotic mo-
lecules (e.g: BCL-X -regulator of programmed cell death, FLIP 
- Fas-associated death domain-like interleukin-1-converting 
enzyme-like inhibitory protein) or lack or aberrant expression 
of MHC class I or II, inhibiting T cell cytotoxic response.20 
On the other hand, escape may result from the develo-
pment of an immunosuppressive state by the tumour's own 
microenvironment, by producing immunosuppressive cytoki-
nes such as vascular endothelial growth factor (VEGF), 
transforming growth factor–beta (TGF-β), IL-10, galectin, or 
indolamine 2,3-dioxygenase (IDO) and/or by recruiting regu-
latory immune cells that promote immunosuppression.9,14,20,23 
Regulatory T cells express inhibitory receptors such as PD-1 
(programmed cell death protein 1), CTLA-4 (cytotoxic T lym-
phocyte-associated protein 4), Tim-3 (T cell immunoglobu-
lin and mucin domain-3) and LAG 3 (Lymphocyte activating 
gene-3), with key roles in inhibiting host-protective anti-tu-
mour responses therefore favouring tumour outgrowth.
2. TARGETED IMMUNOTHERAPIES UNDERLYING 
CANCER IMMUNOEDITING 
Knowing the immune system's dual capacity to recognize 
and destroy cancer but also to shape cancer immunogeni-
city, consistent insights to control cancer via immunological 
means are now well establish. Currently it is widely accepted 
that CTLA-4, PD-1 and its ligand PDL-1 block T cell media-
ted immune system at different levels24 and are important to 
control peripheral T cell response to preclude needless acti-
vation against self-tissues, but may also prevent destruction 
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Figure 1 - The cancer immunoediting concept and the respective three sequential phases: elimination, equilibrium, and escape. The interaction 
between extrinsic factors, the innate/ adaptive immunity of the host and the factors derived from the tumor, promote the tumour growth (Figure adapted 
from Vesely MD et al9 and Schreiber RD et al20).
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of tumour cells.24 Therefore, immunotherapy with different 
agents intended to modulate the host immunity against the 
tumour, namely Interleucin-2 (IL-2), Interferon-α (INF-α), 
vaccines and immune checkpoint inhibitors targeting CTLA-
4 and PD-1/PDL-1 are of utmost importance in the treatment 
of advanced melanoma (unresectable or metastatic) and 
also in an adjuvant setting.25,26
2.1 - Mechanisms of action of immune checkpoint 
inhibitors 
2.1.1 – The cytotoxic T lymphocyte-associated protein 
4 (CTLA-4)
CTLA-4 was originally isolated from cDNA mouse libra-
ries. It was expressed in activated lymphocytes and co-induced 
with T cell mediated cytotoxity, hence the name “cytotoxic T 
lymphocyte-associated protein 4”.27 CTLA-4 is a type I trans-
membrane protein from the immunoglobulin superfamily, 
which also includes MHC class I and II molecules and the T 
cell receptor (TCR). Like other immunoglobulin family mem-
bers, CTLA-4 is expressed on lymphocytes and takes part in 
the process of antigen recognition (35). Peripheral T cell res-
ponse is controlled by two opposing costimulatory receptors 
(CD28 and CTLA-4) that bind to the same ligands (CD80 and 
CD86) on antigen-presenting cells (APCs) and induce a posi-
tive or negative feedback for T cell activation, respectively.28,29 
First, APC activate naïve T cells through MHC class I/TCR bin-
ding in the presence of co-stimulatory connection of CD28 
with CD80 and CD86. Following T cell activation, CTLA-4 is 
upregulated and competes with CD28 for CD80/CD86 bin-
ding, thus attenuating positive co-stimulation by CD28.30,31 
Moreover, CTLA-4 has a higher affinity for the APC´s costimu-
latory receptors  CD80/CD86 than CD28, and therefore dis-
rupts the inicial binding29 and T cells fall into an unrresponsive 
“anergic” state refractory to further stimulation.32,33 In cancer, 
the main immune strategies for tumour escape may include 
the inhability of mutated tumour cells to develop a strong ago-
nistic peptide epitope for T cells and, instead of a protective T 
cell response through CD28/CD80 or 86 ligation, a toleroge-
nic response may occur trhrough the CTLA-4 ligation. Several 
data have shown that enhancement of tumour recognition by 
positive T cell costimulation is beneficial.32-34
Despite its expression by activated CD8+ effector T cells, 
the major role of CTLA-4 seems to be on CD4+ T cells, down-
modulating T cell helper activity and increasing regulatory T 
cell (T reg) immunosupressive function.34 CTLA-4 insufficiency 
is a well established genetic factor for autoimmunity, sugges-
ting the important role of this protein in regulating self-tole-
rance.35,36 In cancer, CTLA-4 blockade promotes anti-tumor 
immunity37 also directly increasing effector CD8+T cells and 
indirectly amplifying immune response by activating helper T 
cells.35,38
2.1.2 – The programed cell death1 (PD-1) and the PD 
ligand 1 (PDL-1)
PD-1 protein is another T-cell co-inhibitory receptor. Its 
structure resembles that of CTLA-4, but has different biologic 
functions and ligands.39,40 PD-1 is expressed by chronically 
stimulated CD4+ and CD8+ T cells and also by B cells and 
natural killer (NK) cells.41 The major role of PD-1 is to limit 
the activity of T cells in peripheral tissues during an inflam-
matory response to foreign as well as self-antigens, in order 
to regulate immune response and limit autoimmunity.42,43 
PD-1 is highly expressed in tumour-infiltrating lymphocytes, 
namely in melanoma, perhaps reflecting a major immune re-
sistance mechanism within the tumour microenvironment.44 
PD-1 expression allows tumour growth despite the presence 
of tumour antigen–specific T cells in the tumour stroma.45 
Within the tumour bed microenvironement  PD-1 predomi-
nantly regulates activity of effector CD8+T cell that display 
an exhausted phenotype and impaired effector function.44
The two ligands for PD-1 are PDL-1 and PDL-2.43 The 
former is highly upregulated on the surface of many solid 
tumour cells, including melanoma.44 PDL-2, has been less 
focused, and its expression is restricted mainly to macropha-
ges, and also on dendritic and B cells.46 Expression of PD-1 
ligands is of outmost importance to determine suitability for 
a therapeutic blockade, because PD-1 only inhibits lym-
phocyte function when it is engaged by its ligands. Two me-
chanisms have been proposed for PDL-1 regulation within 
the tumour microenvironment: innate and adaptive immu-
ne resistance. In some tumours, PDL-1 expression is driven 
by oncogenic signalling pathway within tumour cells (innate 
immune resistance).43 In other tumours, such as melanoma, 
PDL-1 is adaptively induced as a consequence of immune 
responses within the tumour microenvironment.43,47 Specifi-
cally in melanoma, an interesting study48 showed a strong 
correlation between PDL-1 expression on tumour cells and 
both lymphocytic infiltration and intra-tumor INF expression. 
Active antitumor immune response secretes cytokines such 
INF-γ that up-regulate PDL-1 expression. Thus PD-1/PDL-1 
pathway induction may represent an adaptive immune resis-
tance mechanism developed by melanoma cells in respon-
se to endogenous antitumor activity and may explain how 
melanomas escape immune destruction despite endogenous 
antitumor immune responses. 
Taking into account all the previous findings it is quite 
reasonable that PD-1/PDL-1 pathway blockade will enhance 
host immune response against melanoma.49
CONCLUSION
Most cancer cells suffer an enormous number of genetic 
and epigenetic changes that confer plenty of tumour associa-
ted antigens that the host immune system can recognize, but 
many tumor cells escape immune destruction. 
The cancer immunoediting concept advocates the inte-
gration of the effects of the host immune system on tumour 
development and outgrowth. The knowledge of the mecha-
nisms underlying the phases of elimination, equilibrium and 
escape of cancer immunoediting are crucial for the develo-
pment of new cancer immunotherapies.  New insights con-
cerning specific immune resistance mechanisms developed 
by tumours (“immune checkpoints”) decrease antitumour 
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immunity and have a well-established role in the escape me-
chanism. CTLA-4 and PD-1/PDL-1 are the immune check-
points whose mechanisms of action have been extensively 
studied and are currently applied on clinical treatment of se-
veral tumours. 
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